B cell follicle-like structures in multiple sclerosis-With focus on the role of B cell activating factor

Journal of Neuroimmunology

Volumn 273, Issue 1-2, 2014, Pages 1-7

  Haugen, Morten ^a   Frederiksen, Jette L ^a   Degn, Matilda ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

B cell activating factor; B lymphocytes; Follicle like structures; Meningeal inflammation; Multiple sclerosis

Indexed keywords

B CELL ACTIVATING FACTOR; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CXCL13 CHEMOKINE; INTERLEUKIN 17; KI 67 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1;

B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL COMPOSITION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID; CYTOKINE RELEASE; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOLLICLE LIKE STRUCTURE; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MENINGITIS; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TH17 CELL;

B CELL ACTIVATING FACTOR; B LYMPHOCYTES; FOLLICLE-LIKE STRUCTURES; MENINGEAL INFLAMMATION; MULTIPLE SCLEROSIS;

B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHEMOKINE CXCL13; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS;

EID: 84904102114     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.05.010     Document Type: Review

References (52)

1. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Reviews Immunology 2006, 6(3):205-217.
2. Aloisi F., et al. Lymphoid chemokines in chronic neuroinflammation. J. Neuroimmunol. 2008, 198(1-2):106-112.
3. Bagaeva L.V., et al. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J. Immunol. 2006, 176(12):7676-7685.
4. Bettelli E., et al. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 2006, 116(9):2393-2402.
5. Bombardieri M., et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J. Immunol. 2012, 189(7):3767-3776.
6. Calabrese M., et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch. Neurol. 2009, 66(9):1144-1150.
7. Carragher D.M., Rangel-Moreno J., Randall T.D. Ectopic lymphoid tissues and local immunity. Semin. Immunol. 2008, 20(1):26-42.
8. Choi S.R., et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135(10):2925-2937.
9. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372(9648):1502-1517.
10. Corcione A., et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(30):11064-11069.
11. Corsiero E., et al. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol. Lett. 2012, 145(1-2):62-67.
12. Finch D.K., et al. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur. J. Clin. Investig. 2013, 43(5):501-509.
13. Fleige H., et al. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J. Exp. Med. 2014, 211(4):643-651.
14. Franciotta D., et al. B cells and multiple sclerosis. Lancet Neurol. 2008, 7(9):852-858.
15. Franciotta D., et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J. Neuroimmunol. 2011, 230(1-2):160-163.
16. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358(7):676-688.
17. He D., et al. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 2013, 12.
18. Henry R.A., Kendall P.L. CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. J. Immunol. 2010, 185(3):1460-1465.
19. Hjelmström P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J. Leukoc. Biol. 2001, 69(3):331-339.
20. Howell O.W., et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134(9):2755-2771.
21. Kooi E.-J.Ms, et al. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68(9):1021-1028.
22. Krumbholz M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 2005, 201(2):195-200.
23. Krumbholz M., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129(Pt 1):200-211.
24. Krumbholz M., et al. Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131(6):1455-1463.
25. Krumbholz M., et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 2012, 8(11):613-623.
26. Kuenz B., et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008, 3(7):1-7.
27. Lassmann H., Brück W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17(2):210-218.
28. Lassmann H., van Horssen J., Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012, 8(11):647-656.
29. Lee J.S., et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat. Immunol. 2012, 13(2):144-151.
30. Lindén M., et al. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. Mult. Scler. J. 2013, 19(7):863-870.
31. Lovato L., et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011, 134(2):534-541.
32. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47(6):707-717.
33. Lucchinetti C.F., et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365(23):2188-2197.
34. Magliozzi R., et al. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148(1-2):11-23.
35. Magliozzi R., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130(4):1089-1104.
36. Magliozzi R., et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 2010, 68(4):477-493.
37. Magliozzi R., et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J. Neuropathol. Exp. Neurol. 2013, 72(1):29-41.
38. Molnarfi N., et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 2013, 210(13):2921-2937.
39. Nielsen A.S., et al. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology 2013, 81(7):641-649.
40. Owens G.P., et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 2009, 65(6):639-649.
41. Peters A., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35(6):986-996.
42. Popescu B.F.G., Lucchinetti C.F. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012, 12(1):11.
43. Ragheb S., et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult. Scler. J. 2011, 17(7):819-829.
44. Romme Christensen J., et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One 2013, 8(3):1-11.
45. Romme Christensen J., et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014, 1-9.
46. Sellebjerg F., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73(23):2003-2010.
47. Serafini B., et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14(2):164-174.
48. Serafini B., et al. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: Implications for inflammatory tissue injury. J. Neuropathol. Exp. Neurol. 2008, 67(12):1137-1148.
49. Serafini B., et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J. Neuropathol. Exp. Neurol. 2010, 69(7):677-693.
50. Tsuji M., et al. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity 2008, 29(2):261-271.
51. Walker C.A., Huttner A.J., O'Connor K.C. Cortical injury in multiple sclerosis; the role of the immune system. BMC Neurol. 2011, 11(1):152-158.
52. Yamamoto K., et al. Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection. Mucosal Immunol 2014, [Epub ahead of print]. 10.1038/mi.2014.14.